Table 4.
Quality-of-life response analyses at the end of letrozole interventiona
| 2.5 mg QD | 2.5 mg Q-MWF | 1.0 mg Q-MWF | 0.25 mg Q-MWF | Pb | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Domain | Improved (%) |
Stable (%) |
Worsen (%) |
Improved (%) |
Stable (%) |
Worsen (%) |
Improved (%) |
Stable (%) |
Worsen (%) |
Improved (%) |
Stable (%) |
Worsen (%) |
|
| SF-36 | |||||||||||||
| Mental Component summary | 17.9 | 78.6 | 3.6 | 26.9 | 53.9 | 19.2 | 4.4 | 73.9 | 21.7 | 29.6 | 63.0 | 7.4 | 0.19 |
| Physical Component summary | 18.5 | 70.4 | 11.1 | 26.9 | 50.0 | 23.1 | 12.5 | 75.0 | 12.5 | 18.5 | 59.3 | 22.2 | 0.60 |
| Mental health | 17.9 | 67.9 | 14.3 | 26.9 | 46.2 | 26.9 | 8.3 | 66.7 | 25.0 | 25.9 | 66.7 | 7.4 | 0.23 |
| Role-physical | 14.8 | 70.4 | 14.8 | 23.1 | 57.7 | 19.2 | 4.2 | 91.7 | 4.2 | 22.2 | 66.7 | 11.1 | 0.21 |
| Bodily pain | 17.9 | 50.0 | 32.1 | 38.5 | 38.5 | 23.1 | 25.0 | 50.0 | 25.0 | 29.6 | 40.7 | 29.6 | 0.78 |
| Role-emotional | 7.4 | 85.2 | 7.4 | 30.7 | 61.5 | 7.7 | 4.2 | 80.3 | 12.5 | 22.2 | 74.1 | 3.7 | 0.11 |
| Physical function | 32.1 | 42.9 | 25.0 | 26.9 | 65.4 | 7.7 | 0.0 | 91.7 | 8.3 | 22.2 | 55.6 | 22.2 | 0.12 |
| Vitality | 32.1 | 42.9 | 25.0 | 38.5 | 34.6 | 26.9 | 8.3 | 54.2 | 37.5 | 22.2 | 55.6 | 22.2 | 0.22 |
| General health | 17.9 | 78.6 | 3.6 | 15.4 | 73.1 | 11.5 | 8.3 | 83.3 | 8.3 | 14.8 | 63.0 | 22.2 | 0.45 |
| Social function | 3.6 | 75.0 | 21.4 | 19.2 | 57.7 | 23.1 | 4.2 | 87.5 | 8.3 | 25.9 | 55.6 | 18.5 | 0.07 |
| MENQOL | |||||||||||||
| Vasomotor | 17.9 | 39.3 | 42.9 | 30.8 | 38.5 | 30.8 | 20.8 | 33.3 | 45.8 | 7.7 | 38.5 | 53.9 | 0.49 |
| Psycho-social | 35.7 | 60.7 | 3.6 | 34.6 | 50.0 | 15.4 | 12.5 | 62.5 | 25.0 | 34.6 | 46.2 | 19.2 | 0.16 |
| Physical | 25.0 | 53.6 | 21.4 | 26.9 | 50.0 | 23.1 | 16.7 | 58.3 | 25.0 | 15.4 | 50.0 | 34.6 | 0.88 |
| Sexual | 17.9 | 60.7 | 21.4 | 26.9 | 50.0 | 23.1 | 8.3 | 70.8 | 20.8 | 23.1 | 50.0 | 26.9 | 0.67 |
a
The response analysis was based on the proportion of women having worsened (SF-36 score, ≥5-point decrease; MENQOL score, ≥0.5-point increase), improved (SF-36 score, ≥5-point increase; MENQOL, ≥0.5-point decrease) or stable QoL relative to baseline.
b
Fisher’s exact test was performed to compare the response results on each domain of quality of life between the four dose groups.